PLoS ONE 8 , e78154 (2013)
If a consumer can buy Wegovy or Zepbound for $350 directly from the manufacturer, employers are right to ask: Why should our health plan pay more than an individual paying cash? This transparency sets the stage for employers to push for: Mid-cycle GLP-1 repricing or rebate true-ups Most-favored-net clauses guaranteeing parity with manufacturer DTC pricing Dose-specific caps to prevent runaway spend as members titrate upward Even without an immediate financial impact, this public price signal changes the tone of employer-PBM negotiations heading into 2026
These properties make it particularly relevant in contexts where oxidative stress drives tissue damage: photoaging, COPD, post-injury inflammation, and metabolic disease
Although calories and augmented alcohol metabolism are other aspects that might influence the data, these seem unlikely because the GLP-1 pathway suppresses drug responses that are independent of calories and because liraglutide does not change the blood alcohol levels (Vallof et al., 2015)
Paul has no conflicts of interest
While definitive data is still emerging, glucagon receptor activation appears to shift the ratio of fat loss to lean mass loss more favorably